3 Reasons Investors Love Insulet (PODD) Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was ...

Insulet experienced a 5% increase in share price over the past week, a period marked by significant financial advancements and product developments. The company's successful closure of $450 ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...

Just shy of two years after a C-suite reorganization at Insulet, Mark Field has left his position as the inaugural chief technology officer at the Acton medical device manufacturer. Field ...

Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and ...

Independent Advisor Alliance grew its position in Insulet Co. (NASDAQ:PODD – Free Report) by 20.8% in the 4th quarter, according to its most recent filing with the SEC.The firm owned 1,378 ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections of insulin to their first automated pump improved users’ time in a ...

Insulet experienced a 5% increase in share price over the past week, a period marked by significant financial advancements and product developments. The company's successful closure of $450 million in ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 ...

Investing.com -- Moody’s Ratings has raised the Corporate Family Rating (CFR) of Insulet (NASDAQ:PODD) Corporation to Ba3 from B1. The Probability of Default Rating (PDR) also went up to Ba3-PD ...